Equillium, Inc. (EQ) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
EQ Insider Trading Activity
EQ Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $86,433 | 8 | 100 |
Related Transactions
| Zedelmayer Christine | Sr. Vice President and COO | 0 | $0 | 1 | $18,750 | $-18,750 |
| Keyes Jason A | Chief Financial Officer | 0 | $0 | 4 | $30,300 | $-30,300 |
| Tom Penny | Principal Accounting Officer | 0 | $0 | 3 | $37,383 | $-37,383 |
About Equillium, Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Insider Activity of Equillium, Inc.
Over the last 12 months, insiders at Equillium, Inc. have bought $0 and sold $86,433 worth of Equillium, Inc. stock.
On average, over the past 5 years, insiders at Equillium, Inc. have bought $0 and sold $764,624 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
List of Insider Buy and Sell Transactions, Equillium, Inc.
| 2025-01-23 | Sale | Keyes Jason A | Chief Financial Officer | 10,000 0.0275% | $0.65 | $6,500 | -0.23% | |
| 2024-11-14 | Sale | Keyes Jason A | Chief Financial Officer | 10,000 0.0286% | $0.70 | $7,000 | +2.30% | |
| 2024-10-28 | Sale | Zedelmayer Christine | Sr. Vice President and COO | 15,000 0.0481% | $1.25 | $18,750 | -48.32% | |
| 2024-10-28 | Sale | Tom Penny | Principal Accounting Officer | 2,835 0.0091% | $1.25 | $3,544 | -48.32% | |
| 2024-10-25 | Sale | Tom Penny | Principal Accounting Officer | 683 0.0022% | $1.25 | $854 | -40.35% | |
| 2024-09-26 | Sale | Keyes Jason A | Chief Financial Officer | 10,000 0.0286% | $0.81 | $8,100 | -8.86% | |
| 2024-09-16 | Sale | Tom Penny | Principal Accounting Officer | 38,806 0.1083% | $0.85 | $32,985 | -14.70% | |
| 2024-07-16 | Sale | Keyes Jason A | Chief Financial Officer | 10,000 0.0368% | $0.87 | $8,700 | -17.37% | |
| 2022-08-29 | Sale | Keyes Jason A | Chief Financial Officer | 7,000 0.0202% | $2.83 | $19,810 | -68.77% | |
| 2022-06-06 | Sale | Keyes Jason A | Chief Financial Officer | 5,000 0.0147% | $2.52 | $12,600 | -34.00% | |
| 2022-04-04 | Sale | Keyes Jason A | Chief Financial Officer | 8,000 0.0228% | $3.18 | $25,440 | -41.54% | |
| 2021-12-01 | Sale | Keyes Jason A | Chief Financial Officer | 5,000 0.0181% | $5.08 | $25,402 | -45.48% | |
| 2021-11-16 | Sale | Zedelmayer Christine | Sr. Vice President and COO | 11,434 0.0391% | $5.49 | $62,715 | -50.09% | |
| 2021-10-06 | Sale | Connelly Stephen | Chief Scientific Officer | 8,092 0.0282% | $7.01 | $56,706 | -54.17% | |
| 2021-09-27 | Sale | Keyes Jason A | Chief Financial Officer | 8,000 0.0271% | $6.74 | $53,924 | -51.85% | |
| 2021-07-27 | Sale | Keyes Jason A | Chief Financial Officer | 5,000 0.0167% | $5.72 | $28,585 | -32.45% | |
| 2021-06-08 | Sale | Connelly Stephen | Chief Scientific Officer | 10,495 0.0339% | $7.18 | $75,315 | -37.70% | |
| 2021-06-07 | Sale | Connelly Stephen | Chief Scientific Officer | 22,390 0.074% | $7.12 | $159,409 | -35.76% | |
| 2021-06-04 | Sale | Connelly Stephen | Chief Scientific Officer | 13,539 0.0471% | $7.01 | $94,846 | -30.52% | |
| 2021-05-26 | Sale | Keyes Jason A | Chief Financial Officer | 5,000 0.0171% | $6.50 | $32,484 | -20.92% |
EQ Institutional Investors: Active Positions
| Increased Positions | 9 | +26.47% | 102,304 | +1.48% |
| Decreased Positions | 12 | -35.29% | 135,032 | -1.96% |
| New Positions | 6 | New | 98,746 | New |
| Sold Out Positions | 5 | Sold Out | 44,780 | Sold Out |
| Total Postitions | 31 | -8.82% | 7M | -0.47% |
EQ Ownership Change vs Market
Institutional Investor Ownership
| Decheng Capital Llc | $1,868.00 | 12.35% | 4.45M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $354.00 | 2.34% | 841,948 | 0 | 0% | 2024-12-31 |
| Cota Capital Management, Llc | $236.00 | 1.56% | 562,278 | 0 | 0% | 2024-12-31 |
| Renaissance Technologies Llc | $110.00 | 0.73% | 261,400 | -59,773 | -18.61% | 2024-12-31 |
| Geode Capital Management, Llc | $86.00 | 0.57% | 204,385 | 0 | 0% | 2024-12-31 |
| Acadian Asset Management Llc | $46.00 | 0.3% | 108,691 | 0 | 0% | 2024-12-31 |
| Callan Capital, Llc | $42.00 | 0.28% | 99,688 | 0 | 0% | 2025-03-31 |
| Dcf Advisers, Llc | $26.00 | 0.18% | 62,947 | +29,985 | +90.97% | 2024-12-31 |
| State Street Corp | $25.00 | 0.17% | 59,720 | 0 | 0% | 2024-12-31 |
| Susquehanna International Group, Llp | $17.00 | 0.12% | 41,644 | +41,644 | New | 2024-12-31 |